South Korea’s Boryeong has announced the signing of a significant global contract development and manufacturing organization (CDMO) agreement with Joulik Pharma, aimed at supplying the original cytotoxic anti-cancer drug Alimita to seven Southeast Asian countries. This strategic partnership signals a new phase for Boryeong in its drive to establish a robust global footprint in the cytotoxic anti-cancer domain.

The deal marks a critical step for Boryeong, which has been diligently pursuing opportunities to leverage its production and R&D capabilities to compete internationally. Following its acquisition of Alimita’s domestic rights in 2022, Boryeong successfully converted the product into its own production system, optimizing formulation through the launch of liquid products that enhanced its competitiveness. This readiness paved the way for today’s announcement, positioning Boryeong as a reliable supplier for regions prone to supply chain instabilities, especially in life-saving oncology medications.

Boryeong’s strategy is not limited to product supply—it's a comprehensive business transformation. Starting with a contract to supply cytotoxic anticancer drugs with Taiwan Lotus last year and further agreements with Cheflapham and Zyfrexa in July 2025, Boryeong has moved beyond conventional manufacturing, emphasizing enhanced profit structure and global business transformation. These efforts underscore Boryeong’s intent to internalize production and R&D capabilities, adding value through original drug acquisition and development.

Cytotoxic anticancer agents like Alimita remain foundational for chemotherapy worldwide, yet recent years have highlighted risks due to production reductions and supply interruptions by major pharmaceutical organizations. Boryeong’s experience in stable supply of key molecules, including Gemza and Alimita, enables the company to offer resilience and reliability, ensuring that healthcare providers and patients in Southeast Asia have consistent access to critical treatments.

Kim Seong-jin, Boryeong’s Chief Strategy Officer, stated, "I think this cooperation with Joulik Pharma is an important opportunity for Boryeong to expand into a global partnership foundation—CDMO is particularly meaningful in that it is a business structure that can improve the quality of profits rather than simple external growth." The sentiment reflects a wider industry trend where CDMO models are becoming strategic business tools for both margin improvement and value creation, not just capacity expansion.

Boryeong’s investment in global-level production infrastructure, quality assurance, and R&D is projected to solidify its status as a trusted global cytotoxic drug supplier. The partnership is expected to contribute to profit growth starting from the completion of approval processes in each country. Regulatory compliance and registration will be managed in collaboration with Joulik Pharma and local authorities in the seven Southeast Asian nations. This move also positions Boryeong to address shortages and demand volatility that have recently afflicted the oncology drug supply chain in international markets.

For pharmaceutical supply chain leaders, this case exemplifies the rising importance of CDMOs in diversifying risk and meeting regional demand fluctuations for high-value therapies. It also signals increased competition and innovation in the Asia-Pacific region’s contract manufacturing landscape, challenging legacy suppliers and boosting localized capabilities. Boryeong’s transition—from product acquisition and formulation improvement to integrated supply and R&D—offers a blueprint for other Asian manufacturers seeking to elevate their business strategies and achieve long-term global relevance.

As more Southeast Asian countries finalize their respective regulatory approvals, Boryeong anticipates incremental growth opportunities that go well beyond product distribution, encompassing end-to-end production, technical support, and collaborative innovation. For stakeholders including CRO/CMO managers, supply chain strategists, and executive leadership, today’s agreement represents a maturing of the Asian pharmaceutical outsourcing model, promising improved patient access, reliability, and business value.